Navigation Links
DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
Date:10/28/2009

WILMINGTON, Mass., Oct. 28 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units.

"The achievement of this milestone signifies that dermatologists in the U.S. and abroad continue to embrace Levulan PDT for Grade 1 and 2 actinic keratoses (AKs) of the face and scalp and the beneficial outcomes it offers their patients," said Bob Doman, DUSA's President and Chief Executive Officer.

"We believe that Levulan PDT is one of the fastest growing office based procedures in dermatology today, having achieved a 39% compounded annual growth rate in worldwide Kerastick revenues over the past four years," continued Doman.

"PDT is an important, versatile technology that should be integrated more frequently in clinical dermatology practice," said Jill Waibel, M.D., a dermatologist in private practice at Palm Beach Esthetic Dermatology & Laser Center, West Palm Beach, Florida.

"We are excited to have reached the one million Kerastick sales milestone, and believe that significant growth potential exists for Levulan PDT in the treatment of AKs and other potential indications," Doman concluded.

DUSA continues to explore other potential indications for the utilization of Levulan PDT for the treatment of various skin conditions and has initiated a pilot study on Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. ® is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach®. DUSA is researching Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our Web site at www.dusapharma.com.

Forward Looking Statements

Except for historical information, this news release contains certain forward-looking statements that represent our current expectations and beliefs concerning future events, and involve certain known and unknown risk and uncertainties. These forward-looking statements relate to belief concerning the speed of Levulan growth and its potential for additional growth and additional indications. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from future results, performance or achievements expressed or implied by those in the forward-looking statements made in this release. These factors include, without limitation, actions by health regulatory authorities, sufficiency of funds, the regulatory approval process, results of clinical trials, reliance on third party manufacturers, our patent portfolio, and other risks and uncertainties identified in DUSA's Form 10-K for the year ended December 31, 2008, and other SEC filings from time to time.

SOURCE DUSA Pharmaceuticals, Inc.


'/>"/>
SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
2. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
3. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
4. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
5. BioMarin Acquires Huxley Pharmaceuticals, Inc.
6. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
7. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
9. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
10. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
11. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016 The global prefilled syringes market accounted ... expected to grow with a CAGR of 12.9% during ... segment dominated the global prefilled syringes market, with 90.1% ... --> The global market of prefilled syringes is ... geriatric population, increasing demand for vaccines, increasing prevalence of ...
(Date:2/9/2016)... The new report "Global Blood Monitoring & Cardiac Monitoring Devices Market ... group reveals that global market for blood monitoring & cardiac monitoring ... to grow to US$ 24,830.1 million by 2019 at a CAGR ... , Europe , Asia-Pacific ... and Africa . The three major factors ...
(Date:2/9/2016)... -- Increasingly, health care professionals are enhancing patient care and ... With the Vios Monitoring System from Vios Medical, health ... problems before they become serious by continuously tracking and ... the United States . --> ... --> The Vios Monitoring System connects patient-worn sensors, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics, who is celebrating their 25th year ... beginnings to being an internationally recognized leader in their industry. , "We are very ... Lawrence, President of Workrite. “Workrite recognized the importance of good ergonomics before most ...
(Date:2/10/2016)... ... February 09, 2016 , ... Western University of ... oral screenings to 150 children in kindergarten through third grade at Hurley Elementary ... Medicine joined Chinese American Dental Society of Southern California volunteers for Give Kids ...
(Date:2/10/2016)... , ... February 10, 2016 , ... It’s that time ... Davis, the new president of the Interscholastic Athletic Association of Maryland (IAAM), Hall of ... how quickly fitness goals are cast aside. , That’s why one of her first ...
(Date:2/9/2016)... ... , ... February is Heart Awareness Month, and to celebrate Health Quest Chiropractic ... the American Heart Association, New Mexico chapter. , A Heart Rate Variability (HRV) scan ... INSiGHT Pulse Wave Profiler utilizes a non-invasive technology to determine a heart’s ability to ...
(Date:2/9/2016)... California (PRWEB) , ... February ... ... automated print and e-book publishing software, in partnership with Snowfall4pod Digital, creators ... – a comprehensive book publishing, content management, global distribution and print-on-demand network. ...
Breaking Medicine News(10 mins):